- Home
- CCIX vs CRVS Comparison
CCIX vs CRVS Comparison
Compare CCIX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIX
- CRVS
- Stock Information
- Founded
- CCIX 2023
- CRVS 2014
- Country
- CCIX United States
- CRVS United States
- Employees
- CCIX N/A
- CRVS N/A
- Industry
- CCIX
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- CCIX
- CRVS Health Care
- Exchange
- CCIX Nasdaq
- CRVS Nasdaq
- Market Cap
- CCIX 381.7M
- CRVS 335.1M
- IPO Year
- CCIX 2024
- CRVS 2016
- Fundamental
- Price
- CCIX $10.56
- CRVS $4.19
- Analyst Decision
- CCIX
- CRVS Strong Buy
- Analyst Count
- CCIX 0
- CRVS 5
- Target Price
- CCIX N/A
- CRVS $12.38
- AVG Volume (30 Days)
- CCIX 30.3K
- CRVS 419.4K
- Earning Date
- CCIX 11-07-2013
- CRVS 03-18-2025
- Dividend Yield
- CCIX N/A
- CRVS N/A
- EPS Growth
- CCIX N/A
- CRVS N/A
- EPS
- CCIX N/A
- CRVS N/A
- Revenue
- CCIX N/A
- CRVS N/A
- Revenue This Year
- CCIX N/A
- CRVS N/A
- Revenue Next Year
- CCIX N/A
- CRVS N/A
- P/E Ratio
- CCIX N/A
- CRVS N/A
- Revenue Growth
- CCIX N/A
- CRVS N/A
- 52 Week Low
- CCIX $10.00
- CRVS $1.30
- 52 Week High
- CCIX $11.17
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- CCIX N/A
- CRVS 28.71
- Support Level
- CCIX N/A
- CRVS $4.60
- Resistance Level
- CCIX N/A
- CRVS $5.19
- Average True Range (ATR)
- CCIX 0.00
- CRVS 0.30
- MACD
- CCIX 0.00
- CRVS -0.06
- Stochastic Oscillator
- CCIX 0.00
- CRVS 2.01
About CCIX Churchill Capital Corp IX Ordinary Shares
Churchill Capital Corp IX is a blank check company.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).